share_log

榮昌生物：海外監管公告 - 關於2024年向特定對象發行A股股票預案披露的提示性公告

REMEGEN: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

香港交易所 ·  Apr 2 00:19
Summary by Moomoo AI
榮昌生物製藥（煙台）股份有限公司（「公司」）於2024年3月29日召開董事會及監事會會議，審議通過了2024年度向特定對象發行A股股票的預案。該預案及相關文件已在上海證券交易所網站公開披露。公司董事會成員包括執行董事王威東先生等，並由王威東先生於2024年4月2日代表董事會發出公告。公司強調，本次發行股票預案的披露不代表審批機關對發行事項的實質性判斷或批准，並提醒投資者注意相關投資風險。預案的生效和完成尚需股東大會審議通過及相關審批機構的審核或註冊。
榮昌生物製藥（煙台）股份有限公司（「公司」）於2024年3月29日召開董事會及監事會會議，審議通過了2024年度向特定對象發行A股股票的預案。該預案及相關文件已在上海證券交易所網站公開披露。公司董事會成員包括執行董事王威東先生等，並由王威東先生於2024年4月2日代表董事會發出公告。公司強調，本次發行股票預案的披露不代表審批機關對發行事項的實質性判斷或批准，並提醒投資者注意相關投資風險。預案的生效和完成尚需股東大會審議通過及相關審批機構的審核或註冊。
WING CHEONG BIOPHARMACEUTICAL (YANTAI) CO., LTD. (THE “COMPANY”) HELD A BOARD AND SUPERVISORY BOARD MEETING ON MARCH 29, 2024 TO DISCUSS THE APPROVAL OF THE PROPOSAL TO ISSUE A SHARES TO SPECIFIC OBJECTS FOR 2024. The draft and related documents have been publicly disclosed on the website of the Shanghai Stock Exchange. The members of the Company's Board of Directors include Mr. Wang Weidong, the Executive Director, etc., and a notice was issued on behalf of the Board by Mr. Wang Weidong on 2 April 2024. THE COMPANY EMPHASIZES THAT THE DISCLOSURE OF THE PROPOSED SHARE ISSUE DOES NOT CONSTITUTE A JUDGMENT OR APPROVAL OF THE SUBSTANCE OF THE ISSUANCE BY THE APPROVAL AUTHORITY AND REMINDS INVESTORS TO BE AWARE OF THE RELEVANT INVESTMENT RISKS. The implementation and completion of the proposal is subject to approval by the General Meeting and the approval or registration of the relevant approval bodies.
WING CHEONG BIOPHARMACEUTICAL (YANTAI) CO., LTD. (THE “COMPANY”) HELD A BOARD AND SUPERVISORY BOARD MEETING ON MARCH 29, 2024 TO DISCUSS THE APPROVAL OF THE PROPOSAL TO ISSUE A SHARES TO SPECIFIC OBJECTS FOR 2024. The draft and related documents have been publicly disclosed on the website of the Shanghai Stock Exchange. The members of the Company's Board of Directors include Mr. Wang Weidong, the Executive Director, etc., and a notice was issued on behalf of the Board by Mr. Wang Weidong on 2 April 2024. THE COMPANY EMPHASIZES THAT THE DISCLOSURE OF THE PROPOSED SHARE ISSUE DOES NOT CONSTITUTE A JUDGMENT OR APPROVAL OF THE SUBSTANCE OF THE ISSUANCE BY THE APPROVAL AUTHORITY AND REMINDS INVESTORS TO BE AWARE OF THE RELEVANT INVESTMENT RISKS. The implementation and completion of the proposal is subject to approval by the General Meeting and the approval or registration of the relevant approval bodies.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more